Crystal structure of the pyrazinamidase of mycobacterium tuberculosis: Insights into natural and acquired resistance to pyrazinamide

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Petrella, Stéphanie ^a   Gelus Ziental, Nathalie ^a,b   Maudry, Arnaud ^a   Laurans, Caroline ^a,c   Boudjelloul, Rachid ^a   Sougakoff, Wladimir ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER DE ROUBAIX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CYSTEINE; HISTIDINE; IRON; LYSINE; NICOTINAMIDASE; PYRAZINAMIDE; PYRAZINOIC ACID; AMIDASE; AMINO ACID; PYRAZINAMIDE DEAMIDASE; TUBERCULOSTATIC AGENT;

ACINETOBACTER BAUMANNII; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SUBSTRATE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN FOLDING; PROTEIN MOTIF; PYROCOCCUS HORIKOSHII; THERMOSTABILITY; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; ENZYME STABILITY; ENZYMOLOGY; HEAT; MUTAGENESIS; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

ACINETOBACTER BAUMANNII; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PYROCOCCUS HORIKOSHII;

AMIDOHYDROLASES; AMINO ACIDS; ANTITUBERCULAR AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, BACTERIAL; ENZYME STABILITY; HOT TEMPERATURE; IRON; MODELS, MOLECULAR; MUTAGENESIS; MYCOBACTERIUM TUBERCULOSIS; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; PYRAZINAMIDE; SUBSTRATE SPECIFICITY;

EID: 79551528767     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015785     Document Type: Article

References (31)

1. Zhang Y, Mitchison D (2003) The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7: 6-21.
2. Konno K, Feldmann FM, McDermott W (1967) Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 95: 461-469.
3. Scorpio A, Zhang Y (1996) Mutations in pncA, a gene encoding pyrazinamidase/ nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2: 662-667.
4. Scorpio A, Collins D, Whipple D, Cave D, Bates J, et al. (1997) Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol 35: 106-110.
5. Doustdar F, Khosravi AD, Farnia P (2009) Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. Microb Drug Resist 15: 251-256.
6. Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V (1999) Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 43: 1761-1763.
7. Pandey S, Newton S, Upton A, Roberts S, Drinkovic D (2009) Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. Pathology 41: 582-584.
8. Zhang H, Bi LJ, Li CY, Sun ZG, Deng JY, et al. (2009) Mutations found in the pncA gene of Mycobacterium tuberculosis in clinical pyrazinamide-resistant isolates from a local region of China. J Int Med Res 37: 1430-1435.
9. Jureen P, Werngren J, Toro JC, Hoffner S (2008) Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 52: 1852-1854.
10. Sekiguchi J, Nakamura T, Miyoshi-Akiyama T, Kirikae F, Kobayashi I, et al. (2007) Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. J Clin Microbiol 45: 2802-2807.
11. Zimic M, Sheen P, Quiliano M, Gutierrez A, Gilman RH (2010) Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance. Infect Genet Evol 10: 346-349.
12. Lemaitre N, Callebaut I, Frenois F, Jarlier V, Sougakoff W (2001) Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. Biochem J 353: 453-458.
13. Unissa A, Selvakumar N, Hassan S (2010) Insight to pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking. Bioinformation 4: 24-29.
14. Du X, Wang W, Kim R, Yakota H, Nguyen H, et al. (2001) Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. Biochemistry 40: 14166-14172.
15. Fyfe PK, Rao VA, Zemla A, Cameron S, Hunter WN (2009) Specificity and mechanism of Acinetobacter baumanii nicotinamidase: implications for activation of the front-line tuberculosis drug pyrazinamide. Angew Chem Int Ed Engl 48: 9176-9179.
16. Zhang H, Deng JY, Bi LJ, Zhou YF, Zhang ZP, et al. (2008) Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase. FEBS J 275: 753-762.
17. Sheen P, Ferrer P, Gilman RH, Lopez-Llano J, Fuentes P, et al. (2009) Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 89: 109-113.
18. Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, et al. (2001) High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 6: 429-440.
19. Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. Journal of Applied Crystallography 26: 795-800.
20. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. Journal of Applied Crystallography 40: 1297-1300.
21. Brunger AT, Adams PD, Clore GM, Delano WL, Gros P, et al. (1998) Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallography D 54: 905-921.
22. Vagin AA, Steiner RA, Lebedev AA, Potterton L, McNicholas S, et al. (2004) REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallography D 60: 2184-2195.
23. Jones TA, Zou JY, Cowan SW, Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47(Pt 2): 110-119.
24. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
25. Krissinel E, Henrick K (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 60: 2256-2268.
26. DeLano WL (2002) The Pymol Molecular Graphics System. DeLano Scientific, Palo Alto, CA, USA.
27. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, et al. (1983) CHARMM: a program for macromolecular energy minimization and dynamics calculations. Journal of Computational Chemistry 4: 187-217.
28. MacKerell AD, Bashford D, Bellot M, Dunbrack RL, Evanseck JD, et al. (1998) All-atom empirical potential for molecular modelling and dynamics studies of proteins. Journal of Physical Chemistry 102: 3586-3616.
29. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. Journal of Computational Chemistry 19: 1639-1662.
30. Seiner DR, Hegde SS, Blanchard JS (2010) Kinetics and Inhibition of Nicotinamidase from Mycobacterium tuberculosis. Biochemistry 49: 9613-9619.
31. McDonnell PA, Yanchunas J, Newitt JA, Tao L, Kiefer SE, et al. (2009) Assessing compound binding to the Eg5 motor domain using a thermal shift assay. Anal Biochem 392: 59-69.